Literature DB >> 7727646

Infection due to parvovirus B19 in patients infected with human immunodeficiency virus.

E Chernak1, G Dubin, D Henry, S J Naides, R L Hodinka, R R MacGregor, H M Friedman.   

Abstract

Parvovirus B19 has been described as a cause of chronic anemia in immunosuppressed patients, including those infected with human immunodeficiency virus (HIV). In this study serological assays and the polymerase chain reaction (PCR) were used to establish the prevalence of both prior and active infection due to parvovirus B19 among a general population of 105 HIV-infected individuals (cohort I) and among 22 HIV-infected patients with anemia (cohort II). Eight individuals in cohort I (7.6%) had IgG antibodies to parvovirus B19, while none had B19-specific IgM antibodies. In cohort II, four patients (18.2%) had B19-specific IgG antibodies and none had IgM antibodies. Only one person in cohort I (0.95%) and one person in cohort II (4.5%) had evidence on PCR of persistent infection with parvovirus B19; both of these patients lacked IgG and IgM antibodies to parvovirus. Both individuals with B19 viremia were anemic and had CD4 lymphocyte counts suggesting advanced immunosuppression (< 50/mm3). The observed low prevalences of B19 seropositivity and active B19 infection differ from the rates documented in previous studies and indicate that infection with parvovirus B19 is uncommon in some groups of HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7727646     DOI: 10.1093/clinids/20.1.170

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy.

Authors:  Sung-Hsin Kuo; Liang-In Lin; Chee-Jen Chang; Yun-Ru Liu; Kuo-Sin Lin; Ann-Lii Cheng
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Low prevalence of active parvovirus B19 infection in HIV-infected patients.

Authors:  G Raguin; M Leruez-Ville; V Gregoire; M Deplanche; C Leport; F Morinet; J L Vilde
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-10       Impact factor: 3.267

3.  High prevelance of human parvovirus infection in patients with malignant tumors.

Authors:  Yasha Li; Yanming Dong; Jun Jiang; Yongbo Yang; Kaiyu Liu; Yi Li
Journal:  Oncol Lett       Date:  2012-01-03       Impact factor: 2.967

4.  Human immunodeficiency virus/human parvovirus B19 co-infection in blood donors and AIDS patients in Sichuan, China.

Authors:  Miao He; Jiang Zhu; Huimin Yin; Ling Ke; Lei Gao; Zhihong Pan; Xiuhua Yang; Wuping Li
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

5.  Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients.

Authors:  Renata Freire Alves Pereira; Rita de Cássia Nasser Cubel Garcia; Kátia Martins Lopes de Azevedo; Sérgio Setúbal; Marilda Agudo Mendonça Teixeira de Siqueira; Solange Artimos de Oliveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-04       Impact factor: 2.743

6.  Parvovirus B19 DNA detection in treatment-naïve HIV anemic patients in Lagos, Nigeria: a case control study.

Authors:  Oluwaseyi Sedowhe Ashaka; Olumuyiwa Babalola Salu; Ayorinde Babatunde James; Akeeb Oriowo Bola Oyefolu; AbdulAzeez Adeyemi Anjorin; Bamidele Oludare Oke; Mercy Remilekun Orenolu; Sunday Aremu Omilabu
Journal:  Afr Health Sci       Date:  2020-03       Impact factor: 0.927

7.  Isolated Anemia in a 69-Year-Old Man with HIV-1: Features of Pure Red Cell Aplasia Mediated by Chronic Parvovirus-B19 Infection.

Authors:  Jason Wylde; Massimo A Berneri; Jacques A J Malherbe; Sue Davel
Journal:  Am J Case Rep       Date:  2022-07-25

8.  Pathogenicity of pandemic H1N1 influenza A virus in immunocompromised cynomolgus macaques.

Authors:  Van Loi Pham; Misako Nakayama; Yasushi Itoh; Hirohito Ishigaki; Mitsutaka Kitano; Masahiko Arikata; Hideaki Ishida; Naoko Kitagawa; Shintaro Shichinohe; Masatoshi Okamatsu; Yoshihiro Sakoda; Hideaki Tsuchiya; Shinichiro Nakamura; Hiroshi Kida; Kazumasa Ogasawara
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

9.  Status of immunity against PVB19 in HIV-infected patients according to CD4(+) cell count, and antiretroviral therapy regimen groups.

Authors:  Alireza Abdollahi; Saeed Shoar; Sara Sheikhbahaei; Behnaz Mahdaviani; Mehrnaz Rasoulinejad
Journal:  Niger Med J       Date:  2014-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.